Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC).
Sumati Gupta(University of Utah), Neeraj Agarwal(University of Utah), John O Shea(University of Utah), Joshua D. Schiffman(Primary Children's Hospital), Brian K. Dalley(University of Utah), Lisa M. Pappas(University of Utah), Andrew Butterfield(University of Utah), Sunil Sharma(University of Utah), Alexis Weston(Translational Genomics Research Institute), Daniel J. Albertson(University of Utah), Timothy J. Parnell(University of Utah)
Cited by 2
Related Papers
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
|Journal of Clinical Oncology|2021|530
Classifying the evolutionary and ecological features of neoplasms
|Nature reviews. Cancer|2017|455
Comparative oncology: what dogs and other species can teach us about humans with cancer
|Philosophical Transactions of the Royal Society B Biological Sciences|2015|440
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
|The Lancet Oncology|2016|213